ADHD Online Adds Social Media Addiction Assessment to Its Online Diagnostic Platform
As Surgeon General advisory reports teens' use skyrocketing and hurting their development, leader in online mental health diagnosis broadens its...
Brain
ADHD Online Adds Social Media Addiction Assessment to Its Online Diagnostic Platform
As Surgeon General advisory reports teens' use skyrocketing and hurting their development, leader in online mental health diagnosis broadens its...
Ocean Biomedical’s (NASDAQ: OCEA) mRNA-based Vaccine Candidate Generates Over 90% Killing of Malaria Parasites in Non-human Primates, Demonstrating Broad Potential for Ocean’s Program to Address Global and Emerging U.S. Malaria Challenges
Multiple Patents have been received in the U.S. and Internationally for Novel Vaccine Candidate and “Whole New Class” of Malaria...
INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer’s Disease
Analysis of MRI scans in participants from an open label Phase 1b study demonstrates that CDM®, a novel gray matter biomarker, is improved following three months of treatment with XPro1595TM Boca Raton, Florida,...
Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
Results Indicative that CTx-1301 Provides Entire Active-Day Efficacy with Optimal Onset and DurationKANSAS CITY, Kan., July 11, 2023 (GLOBE NEWSWIRE)...
BrainsWay Accelerates International Expansion in India
Multisystem Purchases by Asha Neuromodulation Clinics (ANC) Allow for Increased Access to Deep TMS™BURLINGTON, Mass. and JERUSALEM, July 11, 2023...
AlzeCure Publishes New Disease Modifying Data with NeuroRestore ACD856 Against Alzheimer’s and Cognitive Disorders
STOCKHOLM, SWEDEN / ACCESSWIRE / July 11, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical...
New Disease Modifying Drug for Alzheimer’s Disease Fully Approved by FDA, Highlighting the Crucial Role for Cognetivity in Early Detection and Monitoring
Vital breakthrough for Alzheimer's patients worldwide with Eisai's Leqembi FDA approval; Cognetivity Neurosciences' AI CognICA technology poised to play pivotal...
MyndTec Inc. Announces Debt Settlement Agreement
Mississauga, Ontario--(Newsfile Corp. - July 6, 2023) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), an emerging force in...
First of its kind study into digital self-management support for autistic adults reveals significant improvements in anxiety levels and quality of life
Clinical study by Cornwall NHS Trust and University of Plymouth finds anxiety, self-injurious behaviour, memory, and orientation problems are reduced...
Brain Power Wellness Reviews Latest Annual BPW Staff Retreat
Brain Power Wellness, a holistic, school-based wellness organization, reviews its latest staff retreat, which was held June 20-22, 2023. Brain...
Route 92 Medical Announces Appointment of Chris Hartman as Chief Commercial Officer
Chris Hartman Chris Hartman, Chief Commercial Officer, Route 92 MedicalSAN MATEO, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- Route 92...
Cerevance Announces Presentation at the Alzheimer’s Association International Conference
BOSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel...
Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Mild Traumatic Brain Injury
New data in traumatic brain injury (TBI) builds on prior study in insomnia, which has been shown to have high correlation...
Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer
CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers...
Completion of Enrolment and Treatment in the Phase 1 Study of MTX110 in the Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas (DMGs)
10 July 2023 Biodexa Ltd(“Biodexa” or the “Company”) Completion of Enrolment and Treatment in the Phase 1 Study of MTX110...
BioVie to Present Data Showing How NE3107 Potentially Regulates DNA Methylation of Specific Genes in a Manner Highly Correlated to Observed Improvements in Cognition and Biomarkers of Disease
CARSON CITY, Nev., July 10, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company...
ZyVersa Therapeutics Announces Publication in the Journal Circulation That Demonstrates the Role of Inflammasome Activation in Hypertrophic Heart Disease Induced by Mechanical Stress
Mechanical stress on the heart, such as high blood pressure, initiates NLRP3-induced inflammation through heart-brain interactions, causing heart enlargement (hypertrophic...
Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid Tumors
BOSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the...
Spinogenix Receives Approval from the Australia Human Research Ethics Committee to Initiate a Phase 1 Human Clinical Trial of SPG302, a Novel Regenerative Drug for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
SAN DIEGO, July 10, 2023 (GLOBE NEWSWIRE) -- Spinogenix, Inc., a clinical-stage biopharmaceutical company developing novel small molecule drugs for...